StockIQpro
NASDAQ:PRAX

Praxis Precision Medicines, Inc.

Track all markets on TradingView
Track all markets on TradingView

Praxis Precision Medicines, Inc.'s revenue fell 100.0% in fiscal 2025 to $0. Free cash flow was −$249.1M, and the diluted share count rose 25.7%.Summary generated from Praxis Precision Medicines, Inc.'s SEC filings. Latest annual report filed Feb 19, 2026.

Key statistics

Fiscal 2025 from SEC filings. Methodology
Revenue (FY25)$0
Revenue growth−100.0%
Revenue, 5-yr CAGRn/a
Gross marginn/a
Operating marginn/a
Net marginn/a
ROICn/a
Return on equity−45.8%
Debt / equityn/a
Free cash flow−$249.1M
FCF marginn/a
Share count change+25.7%

Financials

Fiscal years, $M
Item20212022202320242025
Revenuen/a0290
Operating income−167−215−126−200−326
Net income−167−214−123−183−303
Free cash flow−126−185−111−132−249

Recent filings

From SEC EDGAR

Peers

Pharmaceutical preparations